# 5.0 510(k) SUMMARY

SUBMITTED BY:

Mari Meyer   
Regulatory Affairs Specialist   
DiaSorin Inc.   
1951 Northwestern Avenue   
P.O. Box 285   
Stillwater, MN 55082-0285   
Phone (651) 351-5635   
Fax (651) 351-5669   
E-mail: mari.meyer@diasorin.com

NAME OF DEVICE:

Trade Name:

DiaSorin LIAISON® VZV IgG

Common Names/Descriptions:

Immunoassay for the detection of specific IgG antibodies to varicella-zoster virus (VZV IgG).

Classification Names:

Varicella-zoster virus Serological Reagents

Product Code:

LFY

PREDICATE DEVICE:

Diamedix Is-VZV IgG Test System, K981867

DEVICE DESCRIPTION:

ITENDED SE: The DiaSon LIAISON® VZV IgGus hemimieceassy (LIA) zser virus (VZV) inhuman serum. This assay can be used as an aid in the determination of previous infection of varicella-zoster virus.

KIT DECRIPTION: he ethodr e qualitativ deteinaton speci IgG ovaricelazstes A. ea the LIAISON® Analyzer.

Varicella-zoster virus antigen is used for coating magnetic particles (solid phase) and a mouse monoclonal antibody to human IgG is linked to an isoluminol derivative (isoluminol-antibody conjugate). Durg st incubatonan gGantiodes present n calirators spleso controls, the solid phase. After each incubatin, the unbound material is removed with a wash cycle. Durig the second incubation, the antibody conjugate reacts with anti-VZV igG already bound to the solid phase.

Subsequently, the starter reagents are added and a flash chemiluminescence reaction is induced. The lhsata s samples or controls.

# PERFORMANCE DATA:

COMPARATIVE CLINICAL TRIALS: The clinical trials were conducted at two external U.S. Iaboratories an at DiaSorin.Testing was performed on prospectively-collected U.S. samples as defined below.Th mpl    Al®  Gn   sy   si manufacturers' instructions for use.

Specimens that were equivocal by both assays were not included in the percent agreement calculation. P  aiv ulo A®y the calculation o percent positive agreement and percent negative agreement when the corresponding reference assay result was equivocal.

Compares number of samples positive on both assays to sum of all positive samples on the reference assay $^ { + }$ samples equivocal on the reference assay and negative on the LIAISON® VZV IgG. Compared number of samples negative on both assay to sum of all negative samples on the reference assay $^ +$ samples equivocal on the reference assay and positive on the LIAISON® VZV IgG

Prospective samples: Subjects Sent to the Laboratory for varicella-zoster virus testing   

<table><tr><td rowspan=6 colspan=1></td><td rowspan=2 colspan=1>DiaSorinLIAISON® VZV IgG</td><td rowspan=1 colspan=3>VZV IgG ELISA</td><td rowspan=2 colspan=1>Total</td><td rowspan=6 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>659</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>670</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>72</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>663</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>745</td></tr><tr><td rowspan=1 colspan=7>Percent Agreement           Exact 95% confidence interval</td></tr><tr><td rowspan=1 colspan=7>Positive                98.8%     (659/667)                   97.7 - 99.5%Negative               84.4%      (65/77)                    74.4 - 91.7%</td></tr></table>

Prospective Samples: Pregnant Women   

<table><tr><td rowspan=6 colspan=1></td><td rowspan=2 colspan=1>LIAISON® VZVIgG Results</td><td rowspan=1 colspan=4>VZV IgG ELISA Results</td><td rowspan=6 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>645</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>659</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>27</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>650</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>689</td></tr><tr><td rowspan=1 colspan=7>Percent Agreement           Exact 95% confidence interval</td></tr><tr><td rowspan=1 colspan=7>Positive                99.2%  (645/650)                      98.2 - 99.7%Negative              64.1%     (25/39)                      47.6 - 78.8%</td></tr></table>

REPRODUCIBILITY: Reproducibility studies were performed at 3 sites in a five-day protocol outlied in CLSI doent, EP15-A.The stuy nclue 3 ifeent LIAISON® VZV IgGkit lots.Eac ste different lot of the LIAiSON® VZV IgG Assay for the study.A coded panel comprised of 9 frozen repsitory samples, prepared representing negative levels, ow positive tomid-positive analyte levels, n ma h i vs,  y  ch ® controls (Neg Ctl and Pos Ctl) which are marketed in Europe, an internal serum borderline control (011006) and a commercially marketed serum ToRCH Negative and Positive Control (BR Neg Ctl and BR Pos Ctl). Results expressed as an Index value are summarized in the following table.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>Within-run</td><td rowspan=1 colspan=1>Within-run</td><td rowspan=1 colspan=1>Between-run</td><td rowspan=1 colspan=1>Between-run</td><td rowspan=1 colspan=1>Between-site</td><td rowspan=1 colspan=1>Between-site</td><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>Overall</td></tr><tr><td rowspan=1 colspan=1>ID#</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Index</td><td rowspan=1 colspan=1>sd</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>sd</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>sd</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>sd.</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>DiaSorin Neg Ctl</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>30.3</td><td rowspan=1 colspan=1>2.97</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>4.52</td><td rowspan=1 colspan=1>7.87</td><td rowspan=1 colspan=1>3.88</td><td rowspan=1 colspan=1>12.8</td><td rowspan=1 colspan=1>5.64</td><td rowspan=1 colspan=1>18.6</td></tr><tr><td rowspan=1 colspan=1>DiaSorin Pos Ctl</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>434</td><td rowspan=1 colspan=1>42.6</td><td rowspan=1 colspan=1>9.81</td><td rowspan=1 colspan=1>48.9</td><td rowspan=1 colspan=1>9.21</td><td rowspan=1 colspan=1>40.3</td><td rowspan=1 colspan=1>9.29</td><td rowspan=1 colspan=1>62.4</td><td rowspan=1 colspan=1>14.4</td></tr><tr><td rowspan=1 colspan=1>011006 (Cutoff Ctl)</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>246</td><td rowspan=1 colspan=1>22.8</td><td rowspan=1 colspan=1>9.44</td><td rowspan=1 colspan=1>26.4</td><td rowspan=1 colspan=1>10.2</td><td rowspan=1 colspan=1>13.6</td><td rowspan=1 colspan=1>5.54</td><td rowspan=1 colspan=1>33.9</td><td rowspan=1 colspan=1>13.8</td></tr><tr><td rowspan=1 colspan=1>BR Neg Cll(100% serum)</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>&lt;10</td><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>5.53</td><td rowspan=1 colspan=1>18.0</td><td rowspan=1 colspan=1>6.15</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>1.62</td><td rowspan=1 colspan=1>23.0</td><td rowspan=1 colspan=1>8.24</td></tr><tr><td rowspan=1 colspan=1>BR Pos Ctl(100% serum)</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>863</td><td rowspan=1 colspan=1>86.4</td><td rowspan=1 colspan=1>10.2</td><td rowspan=1 colspan=1>70.6</td><td rowspan=1 colspan=1>8.05</td><td rowspan=1 colspan=1>27.8</td><td rowspan=1 colspan=1>3.22</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>12.6</td></tr><tr><td rowspan=1 colspan=1>3314</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>60.2</td><td rowspan=1 colspan=1>3.81</td><td rowspan=1 colspan=1>6.54</td><td rowspan=1 colspan=1>3.74</td><td rowspan=1 colspan=1>5.42</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>4.01</td><td rowspan=1 colspan=1>5.75</td><td rowspan=1 colspan=1>9.54</td></tr><tr><td rowspan=1 colspan=1>3360</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>265</td><td rowspan=1 colspan=1>19.5</td><td rowspan=1 colspan=1>7.35</td><td rowspan=1 colspan=1>29.3</td><td rowspan=1 colspan=1>7.59</td><td rowspan=1 colspan=1>6.88</td><td rowspan=1 colspan=1>9.75</td><td rowspan=1 colspan=1>34.2</td><td rowspan=1 colspan=1>12.9</td></tr><tr><td rowspan=1 colspan=1>3385</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>242</td><td rowspan=1 colspan=1>22.0</td><td rowspan=1 colspan=1>8.98</td><td rowspan=1 colspan=1>26.1</td><td rowspan=1 colspan=1>7.63</td><td rowspan=1 colspan=1>4.67</td><td rowspan=1 colspan=1>9.63</td><td rowspan=1 colspan=1>33.5</td><td rowspan=1 colspan=1>13.8.</td></tr><tr><td rowspan=1 colspan=1>3403</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>8.23</td><td rowspan=1 colspan=1>4.86</td><td rowspan=1 colspan=1>13.1</td><td rowspan=1 colspan=1>5.73</td><td rowspan=1 colspan=1>0.73</td><td rowspan=1 colspan=1>6.96</td><td rowspan=1 colspan=1>14.9</td><td rowspan=1 colspan=1>9.14</td></tr><tr><td rowspan=1 colspan=1>3492</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>276</td><td rowspan=1 colspan=1>24.8</td><td rowspan=1 colspan=1>9.08</td><td rowspan=1 colspan=1>24.4</td><td rowspan=1 colspan=1>7.62</td><td rowspan=1 colspan=1>7.89</td><td rowspan=1 colspan=1>6.08</td><td rowspan=1 colspan=1>33.9</td><td rowspan=1 colspan=1>12.3</td></tr><tr><td rowspan=1 colspan=1>3515</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>252</td><td rowspan=1 colspan=1>27.4</td><td rowspan=1 colspan=1>10.6</td><td rowspan=1 colspan=1>24.9</td><td rowspan=1 colspan=1>8.42</td><td rowspan=1 colspan=1>7.12</td><td rowspan=1 colspan=1>6.25</td><td rowspan=1 colspan=1>36.5</td><td rowspan=1 colspan=1>14.5</td></tr><tr><td rowspan=1 colspan=1>3554</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>291</td><td rowspan=1 colspan=1>26.0</td><td rowspan=1 colspan=1>8.68</td><td rowspan=1 colspan=1>28.6</td><td rowspan=1 colspan=1>7.94</td><td rowspan=1 colspan=1>14.0</td><td rowspan=1 colspan=1>5.83</td><td rowspan=1 colspan=1>41.5</td><td rowspan=1 colspan=1>14.3</td></tr><tr><td rowspan=1 colspan=1>Pos 5</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1530</td><td rowspan=1 colspan=1>227</td><td rowspan=1 colspan=1>14.6</td><td rowspan=1 colspan=1>184</td><td rowspan=1 colspan=1>10.2</td><td rowspan=1 colspan=1>138</td><td rowspan=1 colspan=1>7.02</td><td rowspan=1 colspan=1>291</td><td rowspan=1 colspan=1>19.0</td></tr><tr><td rowspan=1 colspan=1>Pos 9</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>679</td><td rowspan=1 colspan=1>60.6</td><td rowspan=1 colspan=1>9.06</td><td rowspan=1 colspan=1>57.1</td><td rowspan=1 colspan=1>7.79</td><td rowspan=1 colspan=1>38.8</td><td rowspan=1 colspan=1>1.20</td><td rowspan=1 colspan=1>82.7</td><td rowspan=1 colspan=1>12.2</td></tr></table>

BR N  Ie eg e ahethe on signal (RLU) for this sample.

The assay precision peformance was establishe at DiaSorin following a protocol utlined inCLSI n AT p  c hi-ay y quadruplicate over 20 working days on one LIAISoN® instrument and one kit lot.

# Results

The results, expressed as an Index value, are summarized in the following table as sample global mean Index; mean %CV's computed for within run, between run, and total.

<table><tr><td rowspan=1 colspan=1>ID#</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>mean(Index)</td><td rowspan=1 colspan=1>withinrunsd</td><td rowspan=1 colspan=1>withinrun%CV</td><td rowspan=1 colspan=1>betweenrunsd</td><td rowspan=1 colspan=1>betweenrun%CV</td><td rowspan=1 colspan=1>overallsd</td><td rowspan=1 colspan=1>overall%CV</td></tr><tr><td rowspan=1 colspan=1>DiaSorin Neg Ctl</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>36.3</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>8.53</td><td rowspan=1 colspan=1>6.86</td><td rowspan=1 colspan=1>18.90</td><td rowspan=1 colspan=1>7.20</td><td rowspan=1 colspan=1>20.05</td></tr><tr><td rowspan=1 colspan=1>DiaSorin Pos Ctl</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>446</td><td rowspan=1 colspan=1>19.4</td><td rowspan=1 colspan=1>4.41</td><td rowspan=1 colspan=1>86.70</td><td rowspan=1 colspan=1>19.48</td><td rowspan=1 colspan=1>88.62</td><td rowspan=1 colspan=1>20.07</td></tr><tr><td rowspan=1 colspan=1>011006 (Cutoff Ctl)</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>271</td><td rowspan=1 colspan=1>18.3</td><td rowspan=1 colspan=1>6.78</td><td rowspan=1 colspan=1>43.45</td><td rowspan=1 colspan=1>16.06</td><td rowspan=1 colspan=1>45.62</td><td rowspan=1 colspan=1>17.01</td></tr><tr><td rowspan=1 colspan=1>BR Neg CtI(100% serum Ctl)</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>&lt;10</td><td rowspan=1 colspan=1>10.8</td><td rowspan=1 colspan=1>4.14</td><td rowspan=1 colspan=1>31.12</td><td rowspan=1 colspan=1>12.07</td><td rowspan=1 colspan=1>32.39</td><td rowspan=1 colspan=1>12.62</td></tr><tr><td rowspan=1 colspan=1>BR Pos Ctl(100% serum Ctl)</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>952</td><td rowspan=1 colspan=1>64.0</td><td rowspan=1 colspan=1>7.07</td><td rowspan=1 colspan=1>174.41</td><td rowspan=1 colspan=1>18.32</td><td rowspan=1 colspan=1>182.54</td><td rowspan=1 colspan=1>19.25</td></tr><tr><td rowspan=1 colspan=1>3314</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>60.8</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>4.94</td><td rowspan=1 colspan=1>7.46</td><td rowspan=1 colspan=1>12.28</td><td rowspan=1 colspan=1>7.86</td><td rowspan=1 colspan=1>13.00</td></tr><tr><td rowspan=1 colspan=1>3360</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>318</td><td rowspan=1 colspan=1>17.6</td><td rowspan=1 colspan=1>5.45</td><td rowspan=1 colspan=1>52.09</td><td rowspan=1 colspan=1>16.39</td><td rowspan=1 colspan=1>53.23</td><td rowspan=1 colspan=1>16.85</td></tr><tr><td rowspan=1 colspan=1>3385</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>292</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>2.40</td><td rowspan=1 colspan=1>66.92</td><td rowspan=1 colspan=1>22.94</td><td rowspan=1 colspan=1>66.39</td><td rowspan=1 colspan=1>23.02</td></tr><tr><td rowspan=1 colspan=1>3403</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>5.04</td><td rowspan=1 colspan=1>23.78</td><td rowspan=1 colspan=1>14.53</td><td rowspan=1 colspan=1>24.18</td><td rowspan=1 colspan=1>14.80</td></tr><tr><td rowspan=1 colspan=1>3492</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>330</td><td rowspan=1 colspan=1>22.0</td><td rowspan=1 colspan=1>6.83</td><td rowspan=1 colspan=1>50.39</td><td rowspan=1 colspan=1>15.27</td><td rowspan=1 colspan=1>54.36</td><td rowspan=1 colspan=1>16.62</td></tr><tr><td rowspan=1 colspan=1>3515</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>280</td><td rowspan=1 colspan=1>10.2</td><td rowspan=1 colspan=1>3.62</td><td rowspan=1 colspan=1>40.86</td><td rowspan=1 colspan=1>14.60</td><td rowspan=1 colspan=1>41.14</td><td rowspan=1 colspan=1>14.79</td></tr><tr><td rowspan=1 colspan=1>3554</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>286</td><td rowspan=1 colspan=1>21.1</td><td rowspan=1 colspan=1>7.10</td><td rowspan=1 colspan=1>48.00</td><td rowspan=1 colspan=1>16.77</td><td rowspan=1 colspan=1>51.07</td><td rowspan=1 colspan=1>18.00</td></tr><tr><td rowspan=1 colspan=1>Pos 5</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>1761</td><td rowspan=1 colspan=1>97.2</td><td rowspan=1 colspan=1>5.56</td><td rowspan=1 colspan=1>337.11</td><td rowspan=1 colspan=1>19.37</td><td rowspan=1 colspan=1>344.93</td><td rowspan=1 colspan=1>19.79</td></tr><tr><td rowspan=1 colspan=1>Pos 9</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>769</td><td rowspan=1 colspan=1>26.2</td><td rowspan=1 colspan=1>3.38</td><td rowspan=1 colspan=1>127.97</td><td rowspan=1 colspan=1>16.64</td><td rowspan=1 colspan=1>126.33</td><td rowspan=1 colspan=1>16.50</td></tr></table>

BR NeC Index was beow the edg rangfthe assay theroe; the reisn calculatis ebasd on signal (RLU) for this sample.

# CONCLUSION

The submitted material in this premarket notification is complete and supports a substantial equivalence decision. The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

Ms. Mari Meyer   
Regulatory Affairs Specialist DiaSorin Inc.   
1951 Northwestern Avenue P.O. Box 285   
Stillwater, MN 55082-0285

Re: k061820 Trade/Device Name: LIAISON® VZV IgG Regulation Number: 21 CFR 866.3900 Regulation Name: Varicella-Zoster virus Serological Reagents Regulatory Class: Class II Product Code: LFY Dated: February 13, 2007 Received: February 16, 2007

Dear Ms. Meyer:

We have reviewed your Section $5 1 0 ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Intemet address   
http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours, fall, aon

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and   
Radiological Health

# 4.0 INDICATIONS FOR USE

510(k) Number (if known):K00/820

Device Name:

LIAISON® VZV IgG

Indications For Use:

The LIAISON® VZV IgG Assay uses chemiluminescence immunoassay (CLIA) technology on the LIAISON® Analyzer for the qualitative detection of specific IgG antibodies to varicella-zoster virus in human serum. This assay can be used as an aid in the determination of previous infection of varicella-zoster virus.

Section 4

![](images/4f4b00c407e18dd049b04b18c7b95ff0e2f7047b3d0573f611967bc4ba05f699.jpg)

# Office of In Vitro Diagnostic Device Evaluation and Safety

0k061820